1.07 USD
▼-0.09-7.76%
盘后 1.10 +2.80%
2026-11-20
市值
$56.15M
市盈率
—
EPS
-0.24
股息率
—
52 周区间
1.00 – 3.20
成交量
76.39K
Beta
-0.14
目标价
8.33
52W 低 1.0052W 高 3.20
价格走势
公司简介
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.